Exploring QSAR for CYP11B2 binding affinity and CYP11B2/CYP11B1 selectivity of diverse functional compounds using GFA and G/PLS techniques

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 25, Issue 3, 2010, Pages 354-369

  Roy, Kunal ^a   Roy, Partha P ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

CYP11B2; G PLS; GFA; QSAR; Selectivity

Indexed keywords

ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 11B1; ENZYME INHIBITOR; INDAN DERIVATIVE; MOLECULAR SCAFFOLD; NAPHTHALENE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL PARAMETERS; CHEMOMETRICS; DRUG BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EXTERNAL VALIDITY; GENETIC FUNCTION APPROXIMATION; GENETIC PARTIAL LEAST SQUARE; HUMAN; INTERNAL VALIDITY; PARAMETER; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALDOSTERONE SYNTHASE; ANIMALS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MODELS, THEORETICAL; NAPHTHALENES; PROTEIN BINDING; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEROID 11-BETA-HYDROXYLASE;

EID: 77951439430     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756360903179476     Document Type: Article

References (58)

1. Benjamin B, Karsten D, Rita B. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur J Biochem 1998;252:458-466
2. Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyakara K, Miura S, et al. Role of steroid 11beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992;89:1458-1462
3. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004;217:75-79
4. Davies E, MacKenzie SM. Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 2003;30:437-445
5. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiol Vasc Res 2000;47:1-3.
6. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865-879
7. Hlubocká Z, Jáchymová M, Heller S, Umnerová V, Danzig VV, Lánská V, et al. Association of the -344T/C aldosterone synthase gene variant with essential hypertension. Physiol Res 2008 Dec 17. [Epub ahead of print]
8. Chua SC, Szabo P, Vitek A, Grzeschik KH, John M, White PC. Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). Proc Natl Acad Sci USA 1987;84:7193-7197
9. Wagner MJ, Ge Y, Siciliano M, Wells DE. A hybrid phatase using a novel monoclonal antibody and peptide elution, cell mapping panel for regional localization of probes to human chromosome 8. Genomics 1991;10:114-125
10. Mornet E, Dupont J, Vitek A, White PC. Characterizing two genes encoding human steroid 11beta-hydroxylase (P-450(11) beta). J Biol Chem 1989;264:20961-20967
11. Kawamoto T, Mitsuuchi Y, Toda K, Miyahara K, Yokoyama Y, Nakao K, et al. Cloning of cDNA and genomic DNA for human cyto-chrome P-45011beta. FEBS Lett 1990;269:345-349
12. Mulatero P, Schiavone D, Fallo F, Rabbia F, Veglio F. CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 2000;35:694-698
13. Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Makandu ND, et al. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 2003;21:87-95. (Pubitemid 36143513)
14. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr Res 1995;21:437-442
15. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006;48:1005-1011 (Pubitemid 44772697)
16. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008;51:727-733 (Pubitemid 351301527)
17. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res 2004;94:402-409
18. Huang BS, Ahmad M, Tan J, Leenen FHH. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 2007;43:479-486 (Pubitemid 47451422)
19. Lal A, Veinot JP, Leenen FHH. Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 2004;64:437-476 (Pubitemid 39505423)
20. + channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol 2005;288:H2491-7.
21. Huang SB, White AR, Ahmad M, Tan J, Jeng YA, Leenen HHF. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodeling in rats after myocardial infarction. Cardiovasc Res 2009;81:574-581
22. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
23. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-1812 (Pubitemid 32499963)
24. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004;47:1936-1939 (Pubitemid 40110201)
25. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in strokeprone spontaneously hypertensive rats. Hypertension 2002;40:28-33. (Pubitemid 34755975)
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717 (Pubitemid 29407370)
27. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000;61:52-60. (Pubitemid 30246169)
28. Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000;2:451-456
29. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-1411 (Pubitemid 30207899)
30. Rousseau MF, Gurne O, Duprez D, Van Mieghem W, Robert A, Ahn S, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-1601
31. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, Danser AH. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005;46:701-706
32. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, et al. Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension 2005; 46:113-117
33. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999;17:107-114
34. Thai HM, Van HT, Gaballa MA, Goldman S, Raya TE. Effects of AT1 receptor blockade after a myocardial infarct on myocardial fibrosis, stiffness and contractility. Am J Physiol 1999;276:H873-80.
35. Pilon C, Mulatero P, Barzon L, Veglio F, Garonne C, Boscaro M, et al. Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. J Clin Endocrinol Metab 1999;84:4228-4231
36. Ulmschneider S, Müller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem 2005;48:1796-1805 (Pubitemid 40396312)
37. Ulmschneider S, Müller-Vieira U, Klein CD, Antes I, Lengauer T, Hartmann RW. Synthesis and evaluation of (pyridylmethylene-) tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem 2005;48:1563-1575
38. Heim R, Lucas S, Grombein MC, Ries C, Schewe EK, Negri M, et al. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J Med Chem 2008;51:5064-5074
39. Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe EK, et al. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem 2008;51:6138-6149
40. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Barassin C, et al. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2005;48:6632-6642
41. Voets M, Antes I, Scherer C, Müller-Vieira U, Biemel K, Marchais-Oberwinkler S, et al. Synthesis and evaluation of heteroaryl- substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2006;49:2222-2231
42. Lucas S, Heim R, Ries C, Schewe EK, Birk B, Hartmann WR. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1Hquinolin-2-one derivatives. J Med Chem 2008;51:8077-8087
43. Pinto-Bazurco Mendieta MA, Negri M, Jagusch C, Müller-Vieira U, Lauterbach T, Hartmann WR. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J Med Chem 2008; 1:5009-5018
44. Cerius2 version 4.8. San Diego, CA: Accelrys, Inc. (available at: http:// www.accelrys.com/cerius2).
45. Leonard JT, Roy K. On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 2006;25:235-251
46. Hopfinger AJ, Tokarsi JS. Three-dimensional quantitative structureactivity relationship analysis. In: Charifson PS, ed. Practical Applications of Computer-Aided Drug Design. New York: Marcel Dekker, 1997:105-164
47. Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN. Quantitative structure-antitumor activity relationships of camptothecinanalogues: cluster analysis and genetic algorithm-based studies. J Med Chem 2001;44:3254-3263
48. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationship and quantitative structureproperty relationship. J Chem Inf Comput Sci 1994;34:854-866
49. Dunn WJ III, Rogers D. Genetic partial least squares in QSAR. In: Devillers J, ed. Genetic Algorithms in Molecular Modeling. London: Academic Press, 1996:109-130
50. Hasegawa K, Miyashita Y, Funatsu K. GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists. J Chem Inf Comput Sci 1997;37:306-310
51. Snedecor GW, Cochran WG. Statistical Methods. New Delhi: Oxford & IBH Publishing Co. Pvt. Ltd., 1967.
52. Wold S, Eriksson L. Statistical validation of QSAR results. Validation tools. In: van de Waterbeemd H, ed. Chemometric Methods in Molecular Design. Weinheim: VCH, 1995:312-317
53. Debnath AK. Quantitative structure-activity relationship (QSAR): A versatile tool in drug design. In: Ghose AK, Viswanadhan VN, eds. Combinatorial Library Design and Evaluation. New York: Marcel Dekker, 2001:73-129.
54. Roy K. On some aspects of validation of predictive QSAR models. Expert Opin Drug Discov 2007;2:1567-1577
55. Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302-313
56. Roy K, Roy PP. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors. Chem Biol Drug Des 2008;72:370-382
57. Roy PP, Leonard JT, Roy K. Exploring the impact of the size of training sets for the development of predictive QSAR models. Chemom Intell Lab Syst 2008;90:31-42.
58. Eriksson L, Jaworska J, Worth AP, Cronin MTD, McDowell RM, Gramatica P. Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. Environ Health Perspect 2003;111:1361-1375